Celldex Therapeutics Inc
NASDAQ:CLDX
Intrinsic Value
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. [ Read More ]
The intrinsic value of one CLDX stock under the Base Case scenario is 0.6 USD. Compared to the current market price of 37.98 USD, Celldex Therapeutics Inc is Overvalued by 98%.
Valuation Backtest
Celldex Therapeutics Inc
Run backtest to discover the historical profit from buying and selling CLDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Celldex Therapeutics Inc
Current Assets | 431.7m |
Cash & Short-Term Investments | 423.6m |
Receivables | 2.6m |
Other Current Assets | 5.5m |
Non-Current Assets | 33.9m |
PP&E | 6.6m |
Intangibles | 27.2m |
Other Non-Current Assets | 107k |
Current Liabilities | 31.1m |
Accounts Payable | 3.5m |
Accrued Liabilities | 23.6m |
Other Current Liabilities | 4m |
Non-Current Liabilities | 5.3m |
Other Non-Current Liabilities | 5.3m |
Earnings Waterfall
Celldex Therapeutics Inc
Revenue
|
6.9m
USD
|
Operating Expenses
|
-148.9m
USD
|
Operating Income
|
-142m
USD
|
Other Expenses
|
613k
USD
|
Net Income
|
-141.4m
USD
|
Free Cash Flow Analysis
Celldex Therapeutics Inc
What is Free Cash Flow?
CLDX Profitability Score
Profitability Due Diligence
Celldex Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Celldex Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
CLDX Solvency Score
Solvency Due Diligence
Celldex Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Celldex Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLDX Price Targets Summary
Celldex Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CLDX is 72.13 USD with a low forecast of 35.35 USD and a high forecast of 94.5 USD.
Ownership
CLDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CLDX Price
Celldex Therapeutics Inc
Average Annual Return | 206.73% |
Standard Deviation of Annual Returns | 366.28% |
Max Drawdown | -64% |
Market Capitalization | 2.5B USD |
Shares Outstanding | 65 698 700 |
Percentage of Shares Shorted | 11.44% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 132 full-time employees. The firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The firm is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The company operates in development, manufacturing of therapeutics. Company's CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. Its CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, being studied in a Phase II study. The firm's CDX-527, a bispecific antibody that uses active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which it initiated a Phase II study in advanced solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one CLDX stock under the Base Case scenario is 0.6 USD.
Compared to the current market price of 37.98 USD, Celldex Therapeutics Inc is Overvalued by 98%.